Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs
Executive Leadership hires position Zura Bio for Phase 2 clinical.
Noble Financial assumed coverage on shares of Cadrenal Therapeutics (NASDAQ:CVKD – Free Report) in a research note released on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $4.00 price target on the stock. Separately, HC Wainwright reissued a buy rating and set a $3.00 price target on shares of Cadrenal Therapeutics […]
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.